Rhenman & Partners Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.86M	Sell	313,500 -224,000	-42%	-$3.71M	0.6%	57
2025 Q4	$10.2M	Buy	537,500 +190,000	+55%	+$2.73M	0.95%	41
2025 Q3	$3.21M	Buy	347,500 +162,500	+88%	+$1.69M	0.36%	73
2025 Q2	$2.11M	Sell	185,000 -64,336	-26%	-$695K	0.27%	71
2025 Q1	$2.96M	Sell	249,336 -40,664	-14%	-$680K	0.34%	61
2024 Q4	$5.46M	Sell	290,000 -10,000	-3%	-$229K	0.56%	55
2024 Q3	$6.74M	Buy	300,000 +125,607	+72%	+$2.85M	0.55%	58
2024 Q2	$3.64M	Buy	+174,393	New	+$2.72M	0.35%	65

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Rhenman & Partners Asset Management's NRIX Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Nurix Therapeutics (NRIX) stake by 42% in Q1 2026, selling an estimated $3.71M and leaving 313,500 shares worth $4.86M. The position accounts for 0.6% of the portfolio, ranked #57.

Rhenman & Partners Asset Management first reported a position in NRIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $10.2M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Rhenman & Partners Asset Management held 313,500 shares of Nurix Therapeutics worth $4.86M as of Q1 2026.
Rhenman & Partners Asset Management sold 224,000 Nurix Therapeutics shares in Q1 2026, an estimated $3.71M.
Nurix Therapeutics made up 0.6% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #57 holding.
Rhenman & Partners Asset Management first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 8 quarters since.
Rhenman & Partners Asset Management's Nurix Therapeutics position peaked at $10.2M in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.